Presented in part at the Plenary Session of the American Society for Gastrointestinal Endoscopy during Digestive Disease Week 1994 in New Orleans, LA, and during World Congress of Gastroenterology 1994 in Los Angeles, CA. Published in abstract form (Gastrointest Endosc 1994;40:P116).
Endoscopic therapy of sclerosing cholangitis†
Article first published online: 5 DEC 2005
Copyright © 1995 American Association for the Study of Liver Diseases
Volume 21, Issue 3, pages 661–667, March 1995
How to Cite
Lee, J. G., Schutz, S. M., England, R. E., Leung, J. W. and Cotton, P. B. (1995), Endoscopic therapy of sclerosing cholangitis. Hepatology, 21: 661–667. doi: 10.1002/hep.1840210310
- Issue published online: 5 DEC 2005
- Article first published online: 5 DEC 2005
- Manuscript Accepted: 20 SEP 1994
- Manuscript Received: 10 JUN 1994
The efficacy of endoscopic treatment in primary sclerosing cholangitis has not been clearly established. This report presents endoscopic intervention in 53 consecutive patients with this disorder. Pertinent data were abstracted from the GI-TRAC database, medical records, and cholangiograms, and clinical follow-up was obtained by telephone interview of the subjects. Assessed treatment outcomes were clinical symptom, liver function test, and cholangiographic appearance. Between 1986 and 1993, 85 patients with primary sclerosing cholangitis underwent successful ERCP, of which 36 men and 17 women underwent 100 therapeutic endoscopic procedures. Forty-three of 50 dilations, 37 of 38 stentings, 8 of 8 nasobiliary tube placements, and 11 of 17 stone extractions were technically successful. These treatments were complicated by cholangitis or pancreatitis in 15 patients. Clinical follow-up was obtained in 50 of 53 patients who had undergone 85 procedures (median follow-up of 31 months): 28 patients felt better, 21 felt the same, and 1 felt worse. Liver function tests obtained within 3 months of the endoscopic treatment were significantly improved compared with pretreatment values (P < .001). Cholangiograms showed improvement in 36% of the patients, no change in 51%, and the effect of therapy could not be assessed in 13%. Overall, 41 of 53 patients (77%) had improvements of their clinical symptoms, liver function tests, or cholangiograms.